Here we have characterized the mutation patterns of KRAS and TP53 in matched pancreatic tumor and juice samples from 21 PDAC patients, using targeted deep sequencing with Sanger sequencing and PNA clamp assay as complementary methods. This evidence concerns the gene KRAS and pancreatic neoplasm.